S. Boujos
University Health Network · 3 works · 213 citations · h-index 2
Top works
- Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities
- Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
- Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination